دورية أكاديمية
Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients.
| العنوان: | Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. |
|---|---|
| المؤلفون: | Tajuelo A; Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Carretero O; Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), Madrid, Spain., García-Ríos E; Infecciones Víricas e Inmunidad en Enfermos Inmunodeprimidos, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Universidad Internacional de Valencia - VIU, Valencia, Spain., López-Siles M; Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Cano O; Biología Viral, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Vázquez M; Biología Viral, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Más V; Biología Viral, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Rodríguez-Goncer I; Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), Madrid, Spain., Lalueza A; Department of Internal Medicine, Hospital Universitario '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain., López-Medrano F; Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.; Department of Medicine, Universidad Complutense, Madrid, Spain., Juan RS; Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.; Department of Medicine, Universidad Complutense, Madrid, Spain., Fernández-Ruiz M; Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.; Department of Medicine, Universidad Complutense, Madrid, Spain., Aguado JM; Unit of Infectious Diseases, Hospital Universitario '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.; Department of Medicine, Universidad Complutense, Madrid, Spain., McConnell MJ; Intrahospital Infections Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Pérez-Romero P; Infecciones Víricas e Inmunidad en Enfermos Inmunodeprimidos, National Centre for Microbiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. |
| المصدر: | Frontiers in immunology [Front Immunol] 2022 Apr 25; Vol. 13, pp. 878812. Date of Electronic Publication: 2022 Apr 25 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | COVID-19* , Respiratory Insufficiency*, Adult ; Antibodies, Neutralizing ; Antibodies, Viral ; Cross-Sectional Studies ; Humans ; Immunity, Humoral ; Immunoglobulin G ; Immunoglobulin M ; Oxygen ; Prospective Studies ; Research Report ; SARS-CoV-2 |
| مستخلص: | Introduction: There is robust evidence indicating that the SARS-CoV-2-specific humoral response is associated with protection against severe disease. However, relatively little data exist regarding how the humoral immune response at the time of hospital admission correlates with disease severity in unimmunized patients. Our goal was toidentify variables of the humoral response that could potentially serve as prognostic markers for COVID-19 progressionin unvaccinated SARS-CoV-2 patients. Methods: A prospective cross-sectional study was carried out in a cohort of 160 unimmunized, adult COVID-19 patients from the Hospital Universitario 12Octubre. Participants were classified into four clinical groups based on disease severity: non-survivors with respiratory failure (RF), RF survivors, patients requiring oxygen therapy and those not receiving oxygen therapy. Serum samples were taken on admission and IgM, IgG, IgG subclass antibody titers were determined by ELISA, and neutralizing antibody titersusing a surrogate neutralization assay. The differences in the antibody titers between groups and the association between the clinical and analytical characteristics of the patients and the antibody titers were analyzed. Results: Patients that developed RF and survived had IgM titers that were 2-fold higher than non-survivors ( p = 0.001), higher levels of total IgG than those who developed RF and succumbed to infection ( p < 0.001), and than patients who required oxygen therapy ( p < 0.05), and had 5-fold higher IgG1 titers than RF non-survivors ( p < 0.001) and those who needed oxygen therapy ( p < 0.001), and 2-fold higher than patients that did not require oxygen therapy during admission ( p < 0.05). In contrast, RF non-survivorshad the lowest neutralizing antibodylevels, which were significantly lower compared those with RF that survived ( p = 0.03). A positive correlation was found between IgM, total IgG, IgG1 and IgG3 titers and neutralizing antibody titers in the total cohort (p ≤ 0.0036). Conclusions: We demonstrate that patients with RF that survived infection had significantly higher IgM, IgG, IgG1 and neutralizing titers compared to patients with RF that succumb to infection, suggesting that using humoral response variables could be used as a prognostic marker for guiding the clinical management of unimmunized patients admitted to the hospital for SARS-CoV-2 infection. Competing Interests: MJM and PPR are founders and stockholders of the biotech-nology spin-off company Vaxdyn, which develops vaccines for infections caused by MDR bacteria. Vaxdyn had no role in the elaboration of this manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Tajuelo, Carretero, García-Ríos, López-Siles, Cano, Vázquez, Más, Rodríguez-Goncer, Lalueza, López-Medrano, Juan, Fernández-Ruiz, Aguado, McConnell and Pérez-Romero.) |
| التعليقات: | Erratum in: Front Immunol. 2022 Jun 30;13:965809. (PMID: 35990649) |
| References: | Cell Rep Med. 2020 Jun 23;1(3):100040. (PMID: 32835303) J Clin Immunol. 2022 Feb;42(2):240-252. (PMID: 34787773) Clin Infect Dis. 2021 Jan 27;72(2):301-308. (PMID: 33501951) Science. 2020 Sep 18;369(6510):1501-1505. (PMID: 32703906) Lancet Infect Dis. 2020 Dec;20(12):1350-1351. (PMID: 32979317) J Infect Dis. 2021 Jan 4;223(1):62-71. (PMID: 33175145) Clin Infect Dis. 2020 Dec 17;71(10):2688-2694. (PMID: 32497196) Nat Commun. 2021 Jan 4;12(1):63. (PMID: 33397909) Nat Commun. 2022 Feb 17;13(1):915. (PMID: 35177626) Nat Med. 2021 Nov;27(11):2032-2040. (PMID: 34588689) Clin Infect Dis. 2020 Nov 19;71(16):2027-2034. (PMID: 32221519) J Intern Med. 2022 Feb;291(2):232-240. (PMID: 34611927) Nat Commun. 2017 Nov 16;8(1):1528. (PMID: 29142300) JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570) J Clin Microbiol. 2020 Oct 21;58(11):. (PMID: 32826322) Nat Med. 2020 Jul;26(7):1033-1036. (PMID: 32398876) Diabetes Obes Metab. 2020 Oct;22(10):1915-1924. (PMID: 32573903) Sci Immunol. 2020 Jun 11;5(48):. (PMID: 32527802) Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424) Cell Mol Immunol. 2021 Feb;18(2):318-327. (PMID: 33408342) BMC Med. 2022 Jan 21;20(1):31. (PMID: 35057798) Cell. 2020 Dec 10;183(6):1508-1519.e12. (PMID: 33207184) Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462) Nat Commun. 2021 May 11;12(1):2670. (PMID: 33976165) J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9. (PMID: 32710975) Mil Med Res. 2021 Aug 31;8(1):47. (PMID: 34465396) Commun Biol. 2021 Jan 29;4(1):129. (PMID: 33514825) Pediatr Infect Dis J. 1990 Aug;9(8 Suppl):S16-24. (PMID: 2216603) J Clin Virol. 2020 Oct;131:104611. (PMID: 32882666) Front Immunol. 2022 Jan 31;13:830710. (PMID: 35173741) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) EClinicalMedicine. 2021 May;35:100861. (PMID: 33937733) JAMA. 2012 Jun 20;307(23):2526-33. (PMID: 22797452) Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307) Signal Transduct Target Ther. 2020 Sep 2;5(1):180. (PMID: 32879307) J Clin Invest. 2020 Nov 2;130(11):6141-6150. (PMID: 32764200) Front Immunol. 2021 Mar 04;12:632814. (PMID: 33763078) Cell Rep Med. 2021 Jul 20;2(7):100329. (PMID: 34151306) Biosens Bioelectron. 2021 Apr 15;178:113008. (PMID: 33515984) Lancet Infect Dis. 2020 May;20(5):565-574. (PMID: 32213337) Emerg Infect Dis. 2020 Jul;26(7):1478-1488. (PMID: 32267220) Nat Commun. 2020 Sep 17;11(1):4704. (PMID: 32943637) Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. (PMID: 32320677) Nature. 2021 Jul;595(7867):426-431. (PMID: 34126625) BMC Infect Dis. 2021 Aug 21;21(1):855. (PMID: 34418980) Lancet Respir Med. 2020 May;8(5):475-481. (PMID: 32105632) Open Forum Infect Dis. 2021 Jan 05;8(2):ofab005. (PMID: 33614814) JAMA Intern Med. 2021 May 1;181(5):672-679. (PMID: 33625463) J Infect Dis. 2020 Sep 14;222(8):1265-1269. (PMID: 32726417) |
| فهرسة مساهمة: | Keywords: COVID disease severity; IgG; IgM 2; SARS-CoV-2; humoral response |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (Immunoglobulin G) 0 (Immunoglobulin M) S88TT14065 (Oxygen) |
| تواريخ الأحداث: | Date Created: 20220513 Date Completed: 20220517 Latest Revision: 20220822 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9082065 |
| DOI: | 10.3389/fimmu.2022.878812 |
| PMID: | 35547738 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.878812 |